MedPath

A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection

Phase 2
Completed
Conditions
HIV Infections
Registration Number
NCT00000823
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

To determine the relative antiviral activity and safety of zidovudine ( AZT ) and didanosine ( ddI ) alone and in combination, as well as in various sequences of administration.

The relative efficacy of the approved antiretrovirals in early HIV-1 disease is unclear; thus, a study is needed to evaluate the ability of these various nucleoside analogs to limit pathogenicity.

Detailed Description

The relative efficacy of the approved antiretrovirals in early HIV-1 disease is unclear; thus, a study is needed to evaluate the ability of these various nucleoside analogs to limit pathogenicity.

Patients undergo observation for 2 weeks, then are randomized to one of six treatment arms to receive ddI alone or in sequence or combination with AZT for 16-32 weeks, followed by 4 weeks of post-treatment evaluation. The regimens are: ddI alone for 32 weeks; AZT for 16 weeks followed by ddI for 16 weeks; AZT for 16 weeks followed by AZT/ddI combination for 16 weeks; ddI for 16 weeks followed by AZT for 16 weeks; AZT/ddI combination for 32 weeks; and placebo for 32 weeks.

PER AMENDMENT 6/18/96: NOTE: Patients enrolled under version 3 of the study will terminate treatment at week 16 and have a 4 week follow up.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
85
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (22)

Illinois Masonic Med Ctr

🇺🇸

Chicago, Illinois, United States

Harvard (Massachusetts Gen Hosp)

🇺🇸

Boston, Massachusetts, United States

Univ of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Cook County Hosp

🇺🇸

Chicago, Illinois, United States

Rush Presbyterian - Saint Luke's Med Ctr

🇺🇸

Chicago, Illinois, United States

Johns Hopkins Hosp

🇺🇸

Baltimore, Maryland, United States

Methodist Hosp of Indiana / Life Care Clinic

🇺🇸

Indianapolis, Indiana, United States

Ohio State Univ Hosp Clinic

🇺🇸

Columbus, Ohio, United States

Univ of Washington

🇺🇸

Seattle, Washington, United States

San Francisco Gen Hosp

🇺🇸

San Francisco, California, United States

Univ of Colorado Health Sciences Ctr

🇺🇸

Denver, Colorado, United States

Louis A Weiss Memorial Hosp

🇺🇸

Chicago, Illinois, United States

Beth Israel Med Ctr

🇺🇸

New York, New York, United States

Jack Weiler Hosp / Bronx Municipal Hosp

🇺🇸

Bronx, New York, United States

Bellevue Hosp / New York Univ Med Ctr

🇺🇸

New York, New York, United States

Univ of Cincinnati

🇺🇸

Cincinnati, Ohio, United States

Univ of Rochester Medical Center

🇺🇸

Rochester, New York, United States

Univ of North Carolina

🇺🇸

Chapel Hill, North Carolina, United States

Northwestern Univ Med School

🇺🇸

Chicago, Illinois, United States

Brigham and Women's Hosp

🇺🇸

Boston, Massachusetts, United States

Indiana Univ Hosp

🇺🇸

Indianapolis, Indiana, United States

© Copyright 2025. All Rights Reserved by MedPath